Deadlines are 5:00 PM (Eastern). No extensions will be granted.
|Letter of Intent Required
|Oct 01, 2018
|Nov 28, 2018
|Apr 01, 2019
|Jun 01, 2019
Background & Purpose
Please click on the “RFA ANNOUNCEMENT” link in the upper right corner for complete information.
JDRF is committed to the development of novel therapies to improve metabolic control in people with type 1 diabetes (T1D). Toward this goal, JDRF invites applications to pursue preclinical or clinical studies to identify or validate novel targets for T1D metabolic control. Additionally, we invite applications to pursue clinical investigation of T1D pathophysiology toward the future identification and validation of novel targets.
T1D is characterized by the loss of insulin-producing beta cells and consequential metabolic sequela induced by high levels of blood glucose. Insulin therapy, while absolutely essential, is insufficient for most people with T1D to achieve optimal glycemic control and other metabolic outcomes. Thus, adjunct therapies that complement insulin action are critical. Although some validated type 2 diabetes (T2D) drugs (such as GLP-1 receptor agonists and SGLT inhibitors) show clinical efficacy in T1D, additional therapies designed specifically for T1D pathophysiology promise further advances in metabolic control. This RFA is intended to advance the development of adjunctive therapies rooted in T1D biology.